Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Pipeline Review, H2 2017 - Product Image

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Pipeline Review, H2 2017

  • ID: 4410064
  • Report
  • 36 pages
  • Global Markets Direct
1 of 5
Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Pipeline Review, H2 2017

Summary

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Dual specificity protein kinase TTK is an enzyme encoded by the TTK gene. It is associated with cell proliferation, essential for chromosome alignment at the centromere during mitosis and is required for centrosome duplication. It acts as critical mitotic checkpoint protein for accurate segregation of chromosomes during mitosis.

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) pipeline Target constitutes close to 10 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I and Preclinical stages are 3 and 3 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Breast Cancer, Solid Tumor, Colorectal Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and Pancreatic Ductal Adenocarcinoma.

The latest report Dual Specificity Protein Kinase TTK - Pipeline Review, H2 2017, outlays comprehensive information on the Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1)
  • The report reviews Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Introduction

REPORT COVERAGE

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Overview

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Companies Involved in Therapeutics Development

Bayer AG

Les Laboratoires Servier SAS

Nerviano Medical Sciences Srl

Netherlands Translational Research Center BV

Pfizer Inc

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Drug Profiles

BAY-1161909 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1217389 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-271850 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CFI-402257 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-153 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-715 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NTRC-00660 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Mps1 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TTK Protein Kinase for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Tyrosine Threonine Kinase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Dormant Products

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Discontinued Products

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Product Development Milestones

Featured News & Press Releases

Apr 20, 2017: Experimental drug could lead to potent combination in breast and other cancers

Sep 24, 2015: Servier and Nerviano Medical Sciences announce the entry of S 81694, an MPS1 inhibitor, in a first in Human clinical trial

Oct 29, 2012: Nerviano Medical Sciences To Present Four Posters At 24th EORTC-NCI-AACR Symposium

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Bayer AG, H2 2017

Pipeline by Les Laboratoires Servier SAS, H2 2017

Pipeline by Nerviano Medical Sciences Srl, H2 2017

Pipeline by Netherlands Translational Research Center BV, H2 2017

Pipeline by Pfizer Inc, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bayer AG
  • Les Laboratoires Servier SAS
  • Nerviano Medical Sciences Srl
  • Netherlands Translational Research Center BV
  • Pfizer Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll